Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Obseva Sa's Business Segments
Obseva Sa's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/OBSV/segments
https://api.csimarket.com/api/v1/companies/OBSV/geographic
https://api.csimarket.com/api/v1/companies/OBSV/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Annual Results
Revenue by Product & Service Category -
- License and Service51%
- Collaboration Arrangement19.5%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 14 | 51% |
| Collaboration Arrangement | $ 5 | 19.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Obseva Sa
Obseva SA is a biopharmaceutical company headquartered in Geneva, Switzerland. It is focused on developing innovative treatments for women's reproductive health and pregnancy disorders. The company was founded in 2012 and has quickly emerged as a leader in the field.
Obseva is primarily engaged in the research, development, and commercialization of drugs to address unmet medical needs in areas such as endometriosis, uterine fibroids, preterm labor, and preeclampsia. These conditions affect millions of women worldwide and have a significant impact on their health and quality of life.
The company has a robust pipeline of product candidates that are at various stages of development. Its most advanced compound, linzagolix, is being evaluated as a potential treatment for uterine fibroids and endometriosis. Linzagolix is a GnRH receptor antagonist that has shown promising results in clinical trials, demonstrating its potential to reduce pain and improve symptoms in patients.
In addition to linzagolix, Obseva is also developing other drug candidates, including OBE2109 for the treatment of preterm labor and OBE022 for the prevention of preeclampsia. These compounds are in early-stage clinical trials and have shown promising preclinical data.
Obseva has a strong focus on research and development, working closely with leading scientists, clinicians, and academic institutions to advance its pipeline. The company invests heavily in clinical trials to gather robust data on the safety and efficacy of its drugs. It also collaborates with other pharmaceutical companies and research organizations to accelerate the development and commercialization of its product candidates.
In terms of commercialization, Obseva aims to bring its drugs to market globally to benefit women suffering from these reproductive health conditions. The company has a dedicated team of professionals who are experienced in the commercialization of pharmaceutical products. They work closely with regulatory authorities to obtain necessary approvals and licenses for the sale of its drugs.
Obseva is committed to improving women's health and making a positive impact on their lives. The company's mission is to develop safe and effective treatments that provide significant clinical benefits and improve the overall quality of life for women affected by reproductive health disorders.
Overall, Obseva SA is a leading biopharmaceutical company focused on addressing unmet medical needs in women's reproductive health. With a strong pipeline and commitment to research, development, and commercialization, the company is poised to make a significant impact in the field and improve the lives of millions of women around the world.
Obseva is primarily engaged in the research, development, and commercialization of drugs to address unmet medical needs in areas such as endometriosis, uterine fibroids, preterm labor, and preeclampsia. These conditions affect millions of women worldwide and have a significant impact on their health and quality of life.
The company has a robust pipeline of product candidates that are at various stages of development. Its most advanced compound, linzagolix, is being evaluated as a potential treatment for uterine fibroids and endometriosis. Linzagolix is a GnRH receptor antagonist that has shown promising results in clinical trials, demonstrating its potential to reduce pain and improve symptoms in patients.
In addition to linzagolix, Obseva is also developing other drug candidates, including OBE2109 for the treatment of preterm labor and OBE022 for the prevention of preeclampsia. These compounds are in early-stage clinical trials and have shown promising preclinical data.
Obseva has a strong focus on research and development, working closely with leading scientists, clinicians, and academic institutions to advance its pipeline. The company invests heavily in clinical trials to gather robust data on the safety and efficacy of its drugs. It also collaborates with other pharmaceutical companies and research organizations to accelerate the development and commercialization of its product candidates.
In terms of commercialization, Obseva aims to bring its drugs to market globally to benefit women suffering from these reproductive health conditions. The company has a dedicated team of professionals who are experienced in the commercialization of pharmaceutical products. They work closely with regulatory authorities to obtain necessary approvals and licenses for the sale of its drugs.
Obseva is committed to improving women's health and making a positive impact on their lives. The company's mission is to develop safe and effective treatments that provide significant clinical benefits and improve the overall quality of life for women affected by reproductive health disorders.
Overall, Obseva SA is a leading biopharmaceutical company focused on addressing unmet medical needs in women's reproductive health. With a strong pipeline and commitment to research, development, and commercialization, the company is poised to make a significant impact in the field and improve the lives of millions of women around the world.
Obseva SA is a biopharmaceutical company that specializes in the development of innovative therapies focused on womens reproductive health and other related conditions. The company is committed to addressing unmet medical needs through its research and development efforts, encompassing various segments, products, and services. Below is an extensive overview of these components:
Segments
1. Reproductive Health:
- This is the core segment of Obsevas operations, focusing on addressing issues related to womens reproductive functions, including fertility disorders and gynecological conditions. The aim is to provide therapies that improve outcomes for women facing challenges in these areas.
2. Womens Health:
- This segment encompasses a broader range of health conditions specific to women, including hormonal disorders, menstrual irregularities, and menopause-related issues. The focus is on understanding the unique health needs of women and developing solutions tailored to their physiological and psychological well-being.
3. Menstrual and Ovulatory Disorders:
- Within this segment, the company works on products targeting conditions such as polycystic ovary syndrome (PCOS), endometriosis, and other ovulatory dysfunctions. The goal is to provide therapeutic options that alleviate symptoms and improve reproductive health.
4. Endometriosis:
- Obseva has dedicated efforts to developing treatments specifically for endometriosis, a painful condition where tissue similar to the lining inside the uterus grows outside it. This condition often leads to severe pain and can impact fertility, making it a significant focus area for the company.
Products
1. Investigational Therapies:
- Nolasiban: This is an oral oxytocin receptor antagonist that has been in development to enhance the success rates of assisted reproductive technologies (ART), particularly in women undergoing in vitro fertilization (IVF). The therapy aims to improve endometrial receptivity, thereby increasing the likelihood of implantation and pregnancy.
- OSE-127: This is an oral compound aimed at addressing the unmet need in the treatment of endometriosis. It works by modulating immune responses and has shown promise in clinical settings to reduce pain and improve quality of life for patients suffering from this condition.
2. Pipeline Products:
- Obseva is continuously working to expand its pipeline with new investigational products targeting various aspects of reproductive health. These products are in different phases of development, comprising preclinical studies to late-stage clinical trials, focusing on novel technologies and therapeutic approaches.
Services
1. Clinical Trials:
- Obseva is actively involved in clinical research, conducting trials to assess the safety and efficacy of its products. The company collaborates with various stakeholders, including academic institutions and clinical research organizations, to ensure robust study designs and scientific integrity.
2. Patient Support Programs:
- To enhance patient experience and adherence to treatment regimens, Obseva provides support programs that may include education about reproductive health conditions, guidance on therapy administration, and access to resources for managing side effects and treatment expectations.
3. Research Collaborations:
- Obseva may engage in partnerships with other biopharmaceutical companies, research institutions, and healthcare organizations to advance understanding of womens health and facilitate innovative therapeutic solutions. These collaborations can include data sharing, co-development of therapies, and joint clinical studies.
4. Regulatory Affairs:
- The company maintains a robust regulatory affairs function to navigate the complex landscape of drug approval processes. This involves preparing and submitting documentation to regulatory authorities, ensuring compliance with health regulations, and advocating for policies that support womens health innovations.
5. Educational Initiatives:
- Obseva may also partake in initiatives aimed at raising awareness about women’s health issues, supporting healthcare professionals with the latest research findings, and promoting education on reproductive health literacy among patients.
By concentrating on these segments, products, and services, Obseva SA aims to be at the forefront of addressing critical challenges in womens health, continuously seeking innovative solutions to enhance the quality of life for women worldwide. The companys commitment to research and development remains a fundamental aspect of its corporate mission, positioning it as a key player in the biopharmaceutical industry focused on reproductive health.
Segments
1. Reproductive Health:
- This is the core segment of Obsevas operations, focusing on addressing issues related to womens reproductive functions, including fertility disorders and gynecological conditions. The aim is to provide therapies that improve outcomes for women facing challenges in these areas.
2. Womens Health:
- This segment encompasses a broader range of health conditions specific to women, including hormonal disorders, menstrual irregularities, and menopause-related issues. The focus is on understanding the unique health needs of women and developing solutions tailored to their physiological and psychological well-being.
3. Menstrual and Ovulatory Disorders:
- Within this segment, the company works on products targeting conditions such as polycystic ovary syndrome (PCOS), endometriosis, and other ovulatory dysfunctions. The goal is to provide therapeutic options that alleviate symptoms and improve reproductive health.
4. Endometriosis:
- Obseva has dedicated efforts to developing treatments specifically for endometriosis, a painful condition where tissue similar to the lining inside the uterus grows outside it. This condition often leads to severe pain and can impact fertility, making it a significant focus area for the company.
Products
1. Investigational Therapies:
- Nolasiban: This is an oral oxytocin receptor antagonist that has been in development to enhance the success rates of assisted reproductive technologies (ART), particularly in women undergoing in vitro fertilization (IVF). The therapy aims to improve endometrial receptivity, thereby increasing the likelihood of implantation and pregnancy.
- OSE-127: This is an oral compound aimed at addressing the unmet need in the treatment of endometriosis. It works by modulating immune responses and has shown promise in clinical settings to reduce pain and improve quality of life for patients suffering from this condition.
2. Pipeline Products:
- Obseva is continuously working to expand its pipeline with new investigational products targeting various aspects of reproductive health. These products are in different phases of development, comprising preclinical studies to late-stage clinical trials, focusing on novel technologies and therapeutic approaches.
Services
1. Clinical Trials:
- Obseva is actively involved in clinical research, conducting trials to assess the safety and efficacy of its products. The company collaborates with various stakeholders, including academic institutions and clinical research organizations, to ensure robust study designs and scientific integrity.
2. Patient Support Programs:
- To enhance patient experience and adherence to treatment regimens, Obseva provides support programs that may include education about reproductive health conditions, guidance on therapy administration, and access to resources for managing side effects and treatment expectations.
3. Research Collaborations:
- Obseva may engage in partnerships with other biopharmaceutical companies, research institutions, and healthcare organizations to advance understanding of womens health and facilitate innovative therapeutic solutions. These collaborations can include data sharing, co-development of therapies, and joint clinical studies.
4. Regulatory Affairs:
- The company maintains a robust regulatory affairs function to navigate the complex landscape of drug approval processes. This involves preparing and submitting documentation to regulatory authorities, ensuring compliance with health regulations, and advocating for policies that support womens health innovations.
5. Educational Initiatives:
- Obseva may also partake in initiatives aimed at raising awareness about women’s health issues, supporting healthcare professionals with the latest research findings, and promoting education on reproductive health literacy among patients.
By concentrating on these segments, products, and services, Obseva SA aims to be at the forefront of addressing critical challenges in womens health, continuously seeking innovative solutions to enhance the quality of life for women worldwide. The companys commitment to research and development remains a fundamental aspect of its corporate mission, positioning it as a key player in the biopharmaceutical industry focused on reproductive health.
